Genenta Science CEO owns 10% stake through market purchases
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Genenta Science Provides Update on CEO Ownership
December 19, 2025 2:30 AM ESTMILAN and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage gene-therapy company developing hematopoietic stem-cell-based immunotherapies for solid tumors, provides an update regarding the ownership position of its Chief Executive Officer and Co-Founder, Pierluigi Paracchi.
Over time, Mr. Paracchi has acquired 30,000 American Depositary Shares (ADSs) of the Company in total through open-market purchases. As reported in the Companys filings with the U.S. Securities and Exchange Commission (SEC), Mr. Paracchis transactions in the Companys securities have... More
